Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients
FASCINATE-2階段2試驗的子集分析表明，denifanstat改善了難治性脂肪肝肝炎患者的纖維化。
Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity
人工智能（AI）和傳統病理學均顯示，denifanstat具有強大的抗纖維化活性。
FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH
FASN抑制劑治療降低了鼠模型中脂質代謝紊亂和MASH的動脈粥樣硬化發展。
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.
加州聖馬特奧，2024年11月18日（環球新聞社）-- 世紀生物科學公司（Sagimet, 納斯達克:SGMT）是一家處於臨床階段的生物製藥公司，正在開發針對代謝和纖維化病路的新穎治療藥物，今天宣佈在美國肝病研究協會（AASLD）2024年度會議 - 肝病大會上，於2024年11月15日至19日在加州聖迭戈舉行，展示了FASN抑制劑denifanstat的第20億期數據，表明其抗纖維化活性，並展示了FASN抑制在動脈粥樣硬化中的潛在益處。
譯文內容由第三人軟體翻譯。
